| Title: | Autoantibody profile differentiates between inflammatory and noninflammatory bullous pemphigoid |
| Other Titles: | Autoantibody profile differentiates between inflammatory and non-inflammatory bullous pemphigoid |
| Autoantibody profile differentiates BP phenotypes |
| Authors: | Izumi, Kentaro Browse this author →KAKEN DB |
| Nishie, Wataru Browse this author →KAKEN DB |
| Mai, Yosuke Browse this author |
| Wada, Mayumi Browse this author |
| Natsuga, Ken Browse this author →KAKEN DB |
| Ujiie, Hideyuki Browse this author →KAKEN DB |
| Iwata, Hiroaki Browse this author →KAKEN DB |
| Yamagami, Jun Browse this author →KAKEN DB |
| Shimizu, Hiroshi Browse this author →KAKEN DB |
| Keywords: | autoantibody |
| bullous pemphigoid |
| collagen XVII |
| ELISA |
| dipeptidyl peptidase-IV inhibitors |
| Issue Date: | Nov-2016 |
| Publisher: | Elsevier |
| Journal Title: | Journal of investigative dermatology |
| Volume: | 136 |
| Issue: | 11 |
| Start Page: | 2201 |
| End Page: | 2210 |
| Publisher DOI: | 10.1016/j.jid.2016.06.622 |
| PMID: | 27424319 |
| Abstract: | Bullous pemphigoid (BP) is a major autoimmune blistering skin disorder, in which a majority of the autoantibodies (autoAbs) target the juxtamembranous extracellular noncollagenous 16A domain (NC16A) domain of hemidesmosomal collagen XVII. BP-autoAbs may target regions of collagen XVII other than the NC16A domain; however, correlations between epitopes of BP-autoAbs and clinical features have not been fully elucidated. To address correlations between the clinical features and specific epitopes of BP-autoAbs, we evaluated the epitope profiles of BP-autoAbs in 121 patients. A total of 87 patients showed a typical inflammatory phenotype with erythema and autoAbs targeting the anti-NC16A domain, whereas 14 patients showed a distinct noninflammatory phenotype, in which autoAbs specifically targeted the midportion of collagen XVII, but not NC16A. Interestingly, this group clinically showed significantly reduced erythema associated with scant lesional infiltration of eosinophils. Surprisingly, 7 of the 14 cases (50.0%) received dipeptidyl peptidase-IV inhibitors for the treatment of diabetes. Dipeptidyl peptidase-IV inhibitors were used in 3 of 76 (3.9%) typical cases of BP with autoAbs targeting NC16A; thus, dipeptidyl peptidase-IV inhibitors are thought to be involved in the development of atypical noninflammatory BP. This study shows that the autoAb profile differentiates between inflammatory and noninflammatory BP, and that noninflammatory BP may be associated with dipeptidyl peptidase-IV inhibitors. |
| Rights: | © 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Relation: | http://www.jidonline.org/article/S0022-202X%2816%2932100-5/abstract |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/67499 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
